Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability

Cladribine (Mavenclad) is indicated as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability. It is administered orally and is available as a 10 mg tablet at a price...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, October 2018
Series:	CADTH common drug review
Subjects:	Cladribine / Therapeutic Use Multiple Sclerosis, Relapsing-remitting / Drug Therapy Canada Cladribine / Economics Immunosuppressive Agents Cost-benefit Analysis
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK539419
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa